CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates a series of p38 inhibitors for their anti-inflammatory properties, originally targeting inflammatory bowel disease. The goal is to identify patient populations that respond well to these compounds and explore their potential in treating other inflammatory conditions.
The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties.
The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis.
In addition, feedback from licensing partners has indicated that clear activity in a range of other disease mode…
SYNOVO GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Tuebingen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Perugia
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, MANCHESTER
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
